Plus Therapeutics, Inc. financial data

Symbol
PSTV on Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
Location
4200 Marathon Blvd., Suite 200, Austin, TX
State of incorporation
DE
Fiscal year end
December 31
Former names
CYTORI THERAPEUTICS, INC. (to 8/2/2019), MACROPORE INC (to 7/5/2005)
Latest financial report
10-K - Q4 2024 - Mar 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 42.6 % -59.2%
Debt-to-equity -215 % -130%
Return On Equity 195 %
Return On Assets -171 % -74.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 17M shares +298%
Common Stock, Shares, Outstanding 5.9M shares +32.7%
Entity Public Float 8.2M USD +41.4%
Common Stock, Value, Issued 6K USD +20%
Weighted Average Number of Shares Outstanding, Basic 6.64M shares +111%
Weighted Average Number of Shares Outstanding, Diluted 7.7M shares +145%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 10.6M USD +9.19%
General and Administrative Expense 9.94M USD +16.3%
Operating Income (Loss) -14.7M USD -10.3%
Nonoperating Income (Expense) 1.72M USD +34240%
Net Income (Loss) Attributable to Parent -13M USD +2.54%
Earnings Per Share, Basic -1.95 USD/shares +54%
Earnings Per Share, Diluted -2.34 USD/shares +44.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 76K USD -99.1%
Other Assets, Current 1.08M USD -15.5%
Assets, Current 5.26M USD -46.5%
Property, Plant and Equipment, Net 448K USD -50.6%
Operating Lease, Right-of-Use Asset 73K USD -63.9%
Goodwill 372K USD 0%
Other Assets, Noncurrent 12K USD -62.5%
Assets 6.63M USD -41.8%
Accounts Payable, Current 9.47M USD +99.1%
Liabilities, Current 15.6M USD +45%
Operating Lease, Liability, Noncurrent 31K USD -63.5%
Liabilities 15.6M USD +22.3%
Retained Earnings (Accumulated Deficit) -493M USD -2.7%
Stockholders' Equity Attributable to Parent -8.95M USD -564%
Liabilities and Equity 6.63M USD -41.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.51M USD +22.1%
Net Cash Provided by (Used in) Financing Activities -776K USD -257%
Net Cash Provided by (Used in) Investing Activities -364K USD -275%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 6.15M shares +36.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -5.65M USD -4.74%
Interest Paid, Excluding Capitalized Interest, Operating Activities 23K USD -68.5%
Deferred Tax Assets, Valuation Allowance 22.6M USD +15.9%
Deferred Tax Assets, Gross 22.6M USD +15.7%
Operating Lease, Liability 75K USD -63.4%
Payments to Acquire Property, Plant, and Equipment 40K USD -58.8%
Lessee, Operating Lease, Liability, to be Paid 80K USD -63.1%
Property, Plant and Equipment, Gross 3.59M USD +4.24%
Operating Lease, Liability, Current 44K USD -63.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 11K USD -81.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 69K USD -52.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure +9.37%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 5K USD -58.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 11K USD -38.9%
Deferred Tax Assets, Operating Loss Carryforwards 15.4M USD +15%
Preferred Stock, Shares Issued 1.95K shares 0%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 424K USD +3.92%
Operating Lease, Payments 148K USD -26.7%
Additional Paid in Capital 485M USD +1.2%
Preferred Stock, Shares Outstanding 1.95K shares 0%
Depreciation, Depletion and Amortization 155K USD -1.9%
Deferred Tax Assets, Net of Valuation Allowance 15K USD -65.1%
Interest Expense 210K USD -63.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%